Index - P/E - EPS (ttm) -2.21 Insider Own 1.50% Shs Outstand 188.88M Perf Week -5.54%
Market Cap 107.45M Forward P/E - EPS next Y -0.69 Insider Trans -3.04% Shs Float 185.37M Perf Month -22.01%
Income -414.80M PEG - EPS next Q -0.28 Inst Own 94.80% Short Float / Ratio 5.45% / 2.02 Perf Quarter -50.84%
Sales 88.80M P/S 1.21 EPS this Y 31.20% Inst Trans -4.28% Short Interest 10.10M Perf Half Y -79.90%
Book/sh 1.28 P/B 0.46 EPS next Y 47.90% ROA -56.90% Target Price 2.38 Perf Year -84.27%
Cash/sh 2.49 P/C 0.24 EPS next 5Y -7.30% ROE -112.20% 52W Range 0.58 - 5.18 Perf YTD -74.12%
Dividend - P/FCF - EPS past 5Y -32.10% ROI -103.50% 52W High -88.71% Beta 1.09
Dividend % - Quick Ratio 7.90 Sales past 5Y -21.40% Gross Margin 73.70% 52W Low 0.84% ATR 0.05
Employees 216 Current Ratio 8.20 Sales Q/Q -12.90% Oper. Margin - RSI (14) 32.67 Volatility 4.11% 6.23%
Optionable Yes Debt/Eq 0.00 EPS Q/Q -49.20% Profit Margin - Rel Volume 0.61 Prev Close 0.60
Shortable Yes LT Debt/Eq 0.00 Earnings May 09 AMC Payout - Avg Volume 5.00M Price 0.58
Recom 3.30 SMA20 -11.46% SMA50 -22.23% SMA200 -74.99% Volume 3,025,073 Change -2.90%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-23 Upgrade Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade JP Morgan
Neutral → Underweight
May-31-22 Resumed Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade Cowen
Outperform → Market Perform
Mar-14-22 Downgrade William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade Stifel
Buy → Hold
$24 → $5
Mar-14-22 Downgrade BTIG Research
Buy → Neutral
Mar-14-22 Downgrade BofA Securities
Neutral → Underperform
$18 → $6
Mar-09-22 Upgrade Oppenheimer
Perform → Outperform
$21
Nov-08-21 Upgrade The Benchmark Company
Hold → Buy
$20
Sep-10-21 Initiated BofA Securities
Neutral
$18
Jun-28-21 Upgrade Stifel
Hold → Buy
$22 → $24
May-18-21 Resumed Goldman
Neutral
$24
Feb-22-21 Downgrade The Benchmark Company
Buy → Hold
Jan-06-21 Initiated Stifel
Hold
$18
Sep-14-20 Initiated JP Morgan
Neutral
$26
Jun-10-20 Downgrade CFRA
Hold → Sell
Show Previous Ratings
Jun-08-23 12:55PM 11:31AM May-10-23 11:28AM 09:16AM May-09-23 06:45PM
05:41PM
Loading…
05:41PM 04:15PM May-08-23 09:29AM May-04-23 10:00AM May-02-23 10:01AM Apr-27-23 08:30AM Apr-19-23 08:38AM Apr-17-23 05:00PM Apr-16-23 06:30AM Apr-13-23 10:59AM
08:57AM
Loading…
Apr-11-23 08:57AM Apr-10-23 10:07AM Apr-02-23 08:27AM Mar-30-23 11:30AM Mar-29-23 05:44PM Mar-24-23 12:00PM Mar-22-23 09:35AM Mar-14-23 03:43AM Feb-28-23 05:15PM Feb-24-23 10:23AM 07:29AM Feb-23-23 06:20PM 05:24PM 04:30PM Jan-09-23 09:04AM
09:00AM
Loading…
Jan-04-23 09:00AM Dec-12-22 10:05AM Dec-05-22 08:00AM Nov-10-22 09:05AM 07:58AM Nov-09-22 09:00AM Nov-04-22 12:35PM Nov-03-22 06:35PM Oct-28-22 10:00AM Oct-27-22 10:02AM Oct-25-22 06:00PM Oct-24-22 07:55AM Oct-11-22 05:13PM (American City Business Journals)
Oct-07-22 03:42PM (American City Business Journals)
11:21AM Sep-07-22 01:15AM Aug-21-22 09:57AM Aug-16-22 08:30AM Aug-05-22 12:11PM Aug-04-22 06:15PM 04:15PM Jul-26-22 06:00PM Jul-14-22 06:01AM Jul-01-22 06:30AM May-27-22 08:00AM (American City Business Journals)
May-16-22 02:09PM May-06-22 10:07AM May-05-22 05:55PM May-04-22 08:15AM Apr-28-22 03:02PM Apr-27-22 12:00PM Apr-26-22 09:19AM 08:53AM Apr-25-22 06:00PM (American City Business Journals)
05:57PM 04:30PM Apr-22-22 08:30AM Apr-20-22 12:54PM 09:17AM Apr-18-22 05:25PM (American City Business Journals) -23.05%
11:30AM 10:39AM 09:48AM 09:32AM Apr-14-22 04:42PM 04:30PM Apr-05-22 05:50AM Mar-30-22 11:30AM Mar-16-22 12:32PM Mar-15-22 10:38AM Mar-14-22 05:43PM (American City Business Journals) -60.87%
04:27PM (Investor's Business Daily)
12:01PM 08:20AM 07:40AM 07:05AM 06:59AM Mar-04-22 09:22AM Mar-01-22 10:43AM 09:55AM Feb-28-22 05:35PM 04:15PM Feb-17-22 06:00PM 03:02PM Feb-08-22 09:38AM Feb-03-22 01:38PM Jan-31-22 03:35PM (American City Business Journals)
Jan-21-22 01:38PM Jan-20-22 09:38PM Jan-19-22 01:38PM
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBIN HOWARD W President & CEO May 16 Sale 0.72 20,361 14,660 939,797 May 17 08:27 PM Zalevsky Jonathan Chief R&D Officer May 16 Sale 0.72 9,791 7,050 293,388 May 17 08:29 PM Wilson Mark Andrew Chief Legal Officer May 16 Sale 0.72 7,543 5,431 257,680 May 17 08:28 PM ROBIN HOWARD W President & CEO Feb 16 Sale 3.00 19,635 58,905 960,158 Feb 17 08:57 PM Zalevsky Jonathan Chief R&D Officer Feb 16 Sale 3.00 10,484 31,452 303,179 Feb 17 09:00 PM Thomsen Jillian B. Chief Financial Officer Feb 16 Sale 3.00 10,267 30,801 313,497 Feb 17 08:58 PM Wilson Mark Andrew Chief Legal Officer Feb 16 Sale 3.00 8,275 24,825 265,223 Feb 17 08:59 PM ROBIN HOWARD W President & CEO Nov 16 Sale 3.57 38,014 135,710 979,793 Nov 18 06:02 PM Zalevsky Jonathan Chief R&D Officer Nov 16 Sale 3.57 13,460 48,052 313,663 Nov 18 06:05 PM Thomsen Jillian B. Chief Financial Officer Nov 16 Sale 3.57 11,095 39,609 323,764 Nov 18 06:03 PM Wilson Mark Andrew Chief Legal Officer Nov 16 Sale 3.57 8,690 31,023 272,498 Nov 18 06:04 PM Curet Myriam Director Sep 23 Sale 3.16 4,198 13,266 31,777 Sep 26 07:32 PM Ajer Jeffrey Robert Director Sep 23 Sale 3.16 4,198 13,266 38,512 Sep 26 07:25 PM CHESS ROBERT Director Sep 22 Sale 3.19 5,100 16,269 228,179 Sep 26 07:23 PM EASTHAM KARIN Director Sep 13 Sale 3.61 21,267 76,774 13,033 Sep 14 06:01 PM Zalevsky Jonathan Chief R&D Officer Aug 18 Sale 4.65 73,716 342,779 327,123 Aug 19 06:27 PM ROBIN HOWARD W President & CEO Aug 16 Sale 4.76 13,759 65,493 1,017,807 Aug 17 07:39 PM Zalevsky Jonathan Chief R&D Officer Aug 16 Sale 4.76 10,560 50,266 400,839 Aug 17 07:41 PM Wilson Mark Andrew SVP & General Counsel Aug 16 Sale 4.76 3,189 15,180 281,188 Aug 17 07:40 PM Thomsen Jillian B. SVP & Chief Accounting Officer Aug 16 Sale 4.76 2,006 9,549 334,859 Aug 17 07:40 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
